The pharmaceutical landscape for diabetes and weight management medications has undergone a significant shift with Health Canada’s authorization of Dr.…
Read More
Retatrutide Eases Sleep Apnea and Knee Arthritis in New Phase 3 Data, Extending Lilly’s Obesity Lead Over Novo
Eli Lilly announced groundbreaking detailed Phase 3 results for its investigational triple agonist, retatrutide, at the American Diabetes Association’s (ADA)…
Read More
Novo Nordisk’s Wegovy Pill Gains UK Approval Amidst Growing Demand and Competitive Landscape
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Novo Nordisk’s oral semaglutide medication, marketed…
Read More
Novo Nordisk hands a Parkinson’s cell therapy to Cellular Intelligence, a startup trying to design cell behavior
Cellular Intelligence, a burgeoning biotechnology firm formerly known as Somite AI, has announced a significant strategic acquisition, securing global rights…
Read More
Canada Becomes First G7 Nation to Approve Generic Semaglutide as Novo Nordisk Patent Lapses
In a landmark decision poised to reshape the pharmaceutical landscape and significantly impact patient access and healthcare costs, Health Canada…
Read More
Novo Nordisk’s Wegovy Poised for Significant European Expansion Following Positive CHMP Opinions on Oral and High-Dose Injectable Formulations
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has delivered two pivotal positive opinions, paving…
Read More
Novo Nordisk hands a Parkinson’s cell therapy to Cellular Intelligence, a startup trying to design cell behavior
Cellular Intelligence, a rapidly emerging biotech firm previously known as Somite AI, has secured global rights to a pioneering clinical-stage…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
The Canadian healthcare landscape is poised for a significant transformation with Health Canada’s authorization of Dr. Reddy’s Laboratories’ generic semaglutide…
Read More
Novo Nordisk Hands a Parkinson’s Cell Therapy to Cellular Intelligence, a Startup Trying to Design Cell Behavior
In a significant move poised to reshape the landscape of Parkinson’s disease treatment and the broader cell therapy sector, Cellular…
Read More
Canada Becomes First G7 Nation to Approve Generic Semaglutide Following Novo Nordisk Patent Lapse, Paving Way for Enhanced Access and Affordability
In a landmark decision poised to significantly reshape the pharmaceutical landscape for diabetes and obesity management, Health Canada has granted…
Read MoreYOU MAY HAVE MISSED
